Rosen's excitement about AI stems from the ability to move beyond population health theories to deliver truly individualized ...

Molecular analysis identified ABC and GCB subtypes, with the ABC subtype benefiting more from the new regimen. The ...

Grewal, MD, assistant professor at the Winship Cancer Institute at Emory University discusses the significant and concerning ...

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies. The FDA has granted orphan drug designation to ZEN-3694, a novel oral ...

For lenvatinib (Lenvima), which can cause hypertension, patients’ baseline blood pressure should be considered, and they should be monitored for the first 4 to 6 weeks. He recommends oncologists ...

AI transforms cancer treatment by personalizing care and enhancing patient-provider communication, revolutionizing how patients manage their health.

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

Marshall emphasizes the complexity of staying updated with various cancers and treatments, the diverse knowledge bases among ...

Daraxonrasib received FDA orphan drug designation for pancreatic cancer, targeting RAS mutations in pancreatic ductal ...